{
  "docId": "019de074-05b7-71fd-bc3c-27f1b7be8924",
  "docSlug": "c3cb552ef3a6b077a714c97117e1fe86",
  "documentTitle": "Mink Therapeutics | Investor Day Presentation Deck | 92 slides",
  "authorId": "mink-therapeutics",
  "authorName": "MiNK Therapeutics",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2022-11-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 29,
  "pageCount": 92,
  "prevPage": 28,
  "nextPage": 30,
  "slideType": "appendix_methodology",
  "function": "present_framework",
  "density": "balanced",
  "nDataPoints": 0,
  "notes": "The slide uses a process flow diagram to show trial progression and a list-based structure for clinical endpoints.",
  "elementsJson": null,
  "metadataConfidence": 0.95,
  "imagePath": null,
  "slideHref": "/slides/019de074-05b7-71fd-bc3c-27f1b7be8924/29",
  "deckHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924",
  "deckJsonHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924.json",
  "deckAnchorHref": "/decks/019de074-05b7-71fd-bc3c-27f1b7be8924#slide-29",
  "components": [
    {
      "bbox": {
        "h": 0.5,
        "w": 0.45,
        "x": 0.05,
        "y": 0.2
      },
      "kind": "diagram",
      "text": "Trial progression from Part 1 Dose Level 1 to Part 2",
      "attrs": null,
      "subkind": "process",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "14636b2c-3346-41a0-bd53-19ebe6cac6d3",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.6,
        "w": 0.4,
        "x": 0.55,
        "y": 0.2
      },
      "kind": "list",
      "text": "Primary, Secondary, and Exploratory endpoints",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "5ec461a8-9bb3-40fe-9054-4596527262a7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.5,
        "x": 0.04,
        "y": 0.85
      },
      "kind": "paragraph",
      "text": "Expansions at RP2D in solid tumor cancers, including but not limited to NSCLC, HCC, prostate",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9434c6a0-0a60-4053-824e-ecf3f29a49e9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.3,
        "x": 0.6,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "Source: Stevens et al, SITC 2022, Poster 649",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1ec97c4c-d38a-41e5-bc7f-aad30410f7d0",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.8,
        "x": 0.04,
        "y": 0.06
      },
      "kind": "title",
      "text": "Phase 1 Trial of agent-797 (allo-iNKTs) Monotherapy or in Combination with Pembrolizumab or Nivolumab in Solid Tumors",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "18e3edce-cc84-4557-9032-ab1cc14c2434",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [],
  "frameworks": [
    {
      "name": "process",
      "slug": null,
      "matchId": "1e0c0b11-8347-4826-acd9-7a2690dfb673",
      "evidence": "Flowchart showing trial progression",
      "confidence": 0.8
    }
  ],
  "arcBeats": [
    {
      "to": 35,
      "from": 23,
      "beatId": "3ca2588f-ae86-4809-9434-ea06292b2cdd",
      "arcName": "Problem-Agitate-Solution",
      "arcSlug": "problem-agitate-solution",
      "beatName": "Evidence",
      "beatSlug": "evidence",
      "evidence": "The presentation provides preclinical and clinical data supporting iNKT cells' potential",
      "position": 2,
      "confidence": 0.8,
      "parentBeatName": null,
      "parentBeatSlug": null
    }
  ],
  "loops": [
    {
      "to": 35,
      "from": 23,
      "name": "Before After",
      "slug": "21-before-after",
      "bestFor": "Product demos, process improvements, ROI justification",
      "matchId": "d3a14978-bf9f-4a75-b0e8-87c8ef56ddbf",
      "evidence": "The presentation uses before-after comparisons to show iNKT cells' potential",
      "position": 1,
      "objective": "Illustrating the benefits of iNKT cells",
      "structure": "The Old Way (Pain) -> The Moment of Change -> The New Way (Glory) -> The Measurable Delta",
      "confidence": 0.7,
      "description": "Show the dramatic contrast between the old way and the new way through side-by-side comparison"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}